Director/Senior Director, Machine Learning and Engineering at Abata Therapeutics

Berkeley, California, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

BS in computer science, mathematics, chemistry or a related field (demonstrated excellence in prior work is more critical than exact undergraduate coursework)
5+ years work experience as a senior technical contributor in two or more of software engineering, data science, and/or machine learning products (experience applying these in the context of chemistry, biology, and/or drug discovery is preferred)
3+ years of personnel management and team leadership experience, including recruiting, day-to-day management, mentoring, performance evaluation, and team strategy development
A track record of technical leadership excellence in these fields, as evidenced by presentations, publications, or output from teams formerly led
Excellent oral and written communication skills

Responsibilities

Working with the CTO and platform leadership, identify priorities and build the digital execution roadmap aligned with company technical and discovery strategy
Collaborate with laboratory scientists to define specific requirements for each component of this roadmap
Drive execution on this roadmap spanning science and engineering, both through your team and through your own effort as needed
Build and manage a multidisciplinary team, setting a culture of delivery, rapid systematic iteration, and high growth
Present externally and internally in both scientific and business contexts as needed, potentially including conferences, partnering, and fundraising discussions

Skills

Machine Learning

Data Science

Cheminformatics

Software Engineering

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free